Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

UCBJF US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

UCBJF US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Ucb S.a.(UCBJF US)

$337.07+18.325.75%(Market Open · 21:00:00 UTC)
Ask AI
ProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Financials & Metrics

FinancialsChartingShort InterestEmployees

Ucb S.a.(UCBJF US)

$337.07+18.325.75%(Market Open · 21:00:00 UTC)
Ask AI
ProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Financials & Metrics

FinancialsChartingShort InterestEmployees

Ucb S.a. — Company Profile

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UU
CEO
Jean-Christophe Tellier
Headquarters
Brussels, BU, BE
IPO Date
Aug 26, 2008
Employees
10,117
Website
www.ucb.com

Key Metrics

Price
$238.54
Market Cap
$45.41B
Revenue (TTM)
$7.74B
Net Income (TTM)
$1.56B
EPS (TTM)
8.20
P/E (TTM)
0.00
P/B (TTM)
4.18
Dividend Yield
60.53%

Ucb S.a. — Company Profile

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UU
CEO
Jean-Christophe Tellier
Headquarters
Brussels, BU, BE
IPO Date
Aug 26, 2008
Employees
10,117
Website
www.ucb.com

Key Metrics

Price
$238.54
Market Cap
$45.41B
Revenue (TTM)
$7.74B
Net Income (TTM)
$1.56B
EPS (TTM)
8.20
P/E (TTM)
0.00
P/B (TTM)
4.18
Dividend Yield
60.53%
ROE (TTM)
14.34%
ROA (TTM)
8.58%
Operating Margin
25.95%
Beta
0.27

Dividends

Last Dividend
$1.70
Last Yield
0.61%

Summary

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.

Website
www.ucb.com
Location
Brussels, BU, BE
Phone32 2 559 99 99
Employees10,117
CEOJean-Christophe Tellier
Sector
Health Care
Industry
Pharmaceuticals
IPO DateAug 26, 2008

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • United Community Banks (UCB) Is Up 0.89% in One Week: What You Should Know01:01PM
  • UCB Selects Veeva Vault CRM4 Nov
  • Are You Looking for a Top Momentum Pick? Why United Community Banks (UCB) is a Great Choice23 Oct
  • United Community Banks (UCB) Upgraded to Strong Buy: Here's What You Should Know22 Oct
  • UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook22 Oct
  • United Community Banks, Inc. (UCB) Q3 2026 Earnings Call Transcript20 Oct
  • What United Community Banks (UCB) Said on Its Q3 Earnings Call20 Oct
  • United Community Banks (UCB) Reports Q3 Earnings: What Key Metrics Have to Say20 Oct
  • United Community Banks (UCB) Q3 Earnings Match Estimates20 Oct
  • United Community Banks (UCB) Reports Next Week: Wall Street Expects Earnings Growth13 Oct
  • UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript8 Oct
  • UCB SA (OTCMKTS:UCBJF) Receives Consensus Rating of “Moderate Buy” from Brokerages5 Oct
  • Why United Community Banks (UCB) is a Great Dividend Stock Right Now1 Oct
  • UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript23 Sep
  • UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript23 Sep
  • UCB (UCBJY) Upgraded to Buy: Here's Why18 Sep
  • Why United Community Banks (UCB) is a Top Dividend Stock for Your Portfolio15 Sep
  • United Community Banks, Inc. (UCB) Discusses Completion of Strategic Initiatives and Sale of Navitas to Strengthen Financial Position Transcript8 Sep
  • United Community Banks (UCB) is a Top Dividend Stock Right Now: Should You Buy?27 Aug

Key Stats

Trading

Px/Chg 1D$238.54 / +2.18%
Avg Volume699.27
Beta0.27
Mkt Cap45.41B
FD Mkt Cap47.76B

Float

Shrs Out/Float190.36M / 117.24M
Short Float0.01%
Days to Cover999.99
Stock Repurchased$0.00

Current Valuation

EV45.40B
EV/EBITDA0.00
EV/Sales0.00
P/B4.18
P/S0.00
FCF Yield3.00%
ROE14.34%
ROA8.58%
Current Ratio1.38

Dividend

Cash$1.70
Yield60.53%
Yield (TTM)60.53%

Estimates

P/E0.00
Est P/E0.00
Est EPS5.83
Est PEG0.00

Valuation

Metric5Yr AvgJun '22Jun '23Jun '24Jun '25Oct '26
PRICE-BASED RATIOS
Price / Earnings41.5115.2939.3175.0036.0341.94
Price / Sales5.522.802.984.906.2410.68
Price / Book Value2.921.931.812.873.834.18
Price / Free Cash Flow34.0215.2621.9757.8141.7133.38
ENTERPRISE VALUE METRICS
Enterprise Value29,719.417,036.118,433.427,902.039,822.645,402.8
Enterprise Value / Sales5.752.953.345.316.4710.68
Enterprise Value / EBITDA20.7610.6915.7421.8720.2935.24
Enterprise Value / EBIT31.6313.4031.6747.7030.1235.24

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue7.6%5,777.05,517.05,252.06,152.07,738.1
Gross Income7.3%4,339.03,842.03,545.04,400.05,748.8
EBITDA5.9%1,594.01,171.01,276.01,963.02,008.2
EBIT12.1%1,271.0582.0585.01,322.02,008.2
Net Income10.1%1,058.0418.0343.01,065.01,557.4
EPS (Diluted)10.8%5.452.151.765.488.20
BALANCE SHEET
Cash & ST Inv13.7%1,475.01,142.0923.01,757.02,469.1
Total Assets6.3%14,210.015,868.015,539.017,347.018,151.2
Total Liabilities5.8%5,824.06,804.06,564.07,318.07,288.3
Total Shareholder Equity6.7%8,386.09,064.08,975.010,029.010,862.9
CASH FLOW
Net Operating Cash Flow8.6%1,553.01,119.0761.01,242.02,162.2
Cap Ex-13.1%-493.0-371.0-316.0-322.0-280.9
Free Cash Flow15.4%1,060.0748.0445.0920.01,881.3

Enterprise Value Bridge

Millions EUR17 Nov '26
Price (As of 17 Nov '26)327.34
Basic Shares190.36
Market Cap62,312.9
Diluted Shares193.95
Fully Diluted Shares Outstanding193.95
Fully Diluted Market Cap63,489.1
+Consolidated Debt3,582.6
−In-the-Money Convertible Debt—
+Capital Leases140.8
+Operating Leases—
−Cash & Equivalents-764.9
−Short-term Investments-31.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value65,130.7

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

ROE (TTM)
14.34%
ROA (TTM)
8.58%
Operating Margin
25.95%
Beta
0.27

Dividends

Last Dividend
$1.70
Last Yield
0.61%

Summary

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.

Website
www.ucb.com
Location
Brussels, BU, BE
Phone32 2 559 99 99
Employees10,117
CEOJean-Christophe Tellier
Sector
Health Care
Industry
Pharmaceuticals
IPO DateAug 26, 2008

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • United Community Banks (UCB) Is Up 0.89% in One Week: What You Should Know01:01PM
  • UCB Selects Veeva Vault CRM4 Nov
  • Are You Looking for a Top Momentum Pick? Why United Community Banks (UCB) is a Great Choice23 Oct
  • United Community Banks (UCB) Upgraded to Strong Buy: Here's What You Should Know22 Oct
  • UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook22 Oct
  • United Community Banks, Inc. (UCB) Q3 2026 Earnings Call Transcript20 Oct
  • What United Community Banks (UCB) Said on Its Q3 Earnings Call20 Oct
  • United Community Banks (UCB) Reports Q3 Earnings: What Key Metrics Have to Say20 Oct
  • United Community Banks (UCB) Q3 Earnings Match Estimates20 Oct
  • United Community Banks (UCB) Reports Next Week: Wall Street Expects Earnings Growth13 Oct
  • UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript8 Oct
  • UCB SA (OTCMKTS:UCBJF) Receives Consensus Rating of “Moderate Buy” from Brokerages5 Oct
  • Why United Community Banks (UCB) is a Great Dividend Stock Right Now1 Oct
  • UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript23 Sep
  • UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript23 Sep
  • UCB (UCBJY) Upgraded to Buy: Here's Why18 Sep
  • Why United Community Banks (UCB) is a Top Dividend Stock for Your Portfolio15 Sep
  • United Community Banks, Inc. (UCB) Discusses Completion of Strategic Initiatives and Sale of Navitas to Strengthen Financial Position Transcript8 Sep
  • United Community Banks (UCB) is a Top Dividend Stock Right Now: Should You Buy?27 Aug

Key Stats

Trading

Px/Chg 1D$238.54 / +2.18%
Avg Volume699.27
Beta0.27
Mkt Cap45.41B
FD Mkt Cap47.76B

Float

Shrs Out/Float190.36M / 117.24M
Short Float0.01%
Days to Cover999.99
Stock Repurchased$0.00

Current Valuation

EV45.40B
EV/EBITDA0.00
EV/Sales0.00
P/B4.18
P/S0.00
FCF Yield3.00%
ROE14.34%
ROA8.58%
Current Ratio1.38

Dividend

Cash$1.70
Yield60.53%
Yield (TTM)60.53%

Estimates

P/E0.00
Est P/E0.00
Est EPS5.83
Est PEG0.00

Valuation

Metric5Yr AvgJun '22Jun '23Jun '24Jun '25Oct '26
PRICE-BASED RATIOS
Price / Earnings41.5115.2939.3175.0036.0341.94
Price / Sales5.522.802.984.906.2410.68
Price / Book Value2.921.931.812.873.834.18
Price / Free Cash Flow34.0215.2621.9757.8141.7133.38
ENTERPRISE VALUE METRICS
Enterprise Value29,719.417,036.118,433.427,902.039,822.645,402.8
Enterprise Value / Sales5.752.953.345.316.4710.68
Enterprise Value / EBITDA20.7610.6915.7421.8720.2935.24
Enterprise Value / EBIT31.6313.4031.6747.7030.1235.24

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue7.6%5,777.05,517.05,252.06,152.07,738.1
Gross Income7.3%4,339.03,842.03,545.04,400.05,748.8
EBITDA5.9%1,594.01,171.01,276.01,963.02,008.2
EBIT12.1%1,271.0582.0585.01,322.02,008.2
Net Income10.1%1,058.0418.0343.01,065.01,557.4
EPS (Diluted)10.8%5.452.151.765.488.20
BALANCE SHEET
Cash & ST Inv13.7%1,475.01,142.0923.01,757.02,469.1
Total Assets6.3%14,210.015,868.015,539.017,347.018,151.2
Total Liabilities5.8%5,824.06,804.06,564.07,318.07,288.3
Total Shareholder Equity6.7%8,386.09,064.08,975.010,029.010,862.9
CASH FLOW
Net Operating Cash Flow8.6%1,553.01,119.0761.01,242.02,162.2
Cap Ex-13.1%-493.0-371.0-316.0-322.0-280.9
Free Cash Flow15.4%1,060.0748.0445.0920.01,881.3

Enterprise Value Bridge

Millions EUR17 Nov '26
Price (As of 17 Nov '26)327.34
Basic Shares190.36
Market Cap62,312.9
Diluted Shares193.95
Fully Diluted Shares Outstanding193.95
Fully Diluted Market Cap63,489.1
+Consolidated Debt3,582.6
−In-the-Money Convertible Debt—
+Capital Leases140.8
+Operating Leases—
−Cash & Equivalents-764.9
−Short-term Investments-31.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value65,130.7

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US